The First Commercial Breath-Based Test for Cancer Screening

To save lives through early noninvasive cancer detection.

Why invest in breath based cancer screening?

Global cancer diagnostics market valued at USD 138 billion (2022), projected to reach USD 279 billion (2032).
Valuation range projected between USD 500 million – USD 1.5 billion depending on FDA approval and global rollout.
Pending USD 5 million annual revenue agreement with a major New York lab operator starting Q1 2025.

FDA-approved CLIA laboratory in New York.
Partnerships with ACCUON Labs, RUA Diagnostics, and ChromX Health for international distribution.
Commercial launch set for New York (Q1 2025) and Kuala Lumpur (Q4 2025).

94.9% accuracy for lung cancer detection.
Results delivered in 30 minutes — faster, cheaper, and more accurate than competitors.
Backed by AI and cloud computing for biomarker analysis.

Cancer is the #2 cause of death worldwide, with one in six deaths attributed to it.
Current methods (blood/stool tests, imaging) are slow, invasive, costly, and less accurate.
BreathDX is positioned to become the Amazon of diagnostic testing: scalable, accessible, and globally deployable.

Strong Exit Pathways
Targeted IPO or strategic sale within 24–36 months, with potential acquirers including Roche, Siemens, Thermo Fisher, and Medtronic.
Valuation Upside
Current valuations range between USD 500 million – USD 1.5 billion depending on FDA approvals and global rollout milestones.
Strategic Partnerships
Backed by global players like ACCUON Labs, RUA Diagnostics, ChromX Health, and Holista Colltech for international distribution and manufacturing.

Unmatched Technology

Proprietary Micro Gas Chromatography device developed at the University of Michigan, with over USD 25M in R&D investment.

Scalable Market Opportunity

Addressing a USD 279 billion market with noninvasive, rapid testing.

Strong Exit Potential

Clear IPO / M&A pathways with global healthcare giants like Roche, Siemens, and Thermo Fisher.

First-Mover Advantage

No other FDA-cleared commercial breath test for cancer; significant barriers to entry.